The Drug Enforcement Administration proposes to adjust the 2024 aggregate production quotas for several controlled substances in schedules I and II of the Controlled Substances Act. Additionally as DEA announced in an April 29 2024 letter to DEA-registered manufacturers procurement quotas for commercial manufacturing of a schedule II controlled substance will be calculated on a semi-annual basis except for injectable drug products containing schedule II controlled substances which will be calculated on an annual basis.